HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV)
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …
COVID-19 and HIV infection co-pandemics and their impact: a review of the literature
S Gatechompol, A Avihingsanon, O Putcharoen… - AIDS research and …, 2021 - Springer
Coronavirus disease 2019 (COVID-19) was first detected in December 2019. In March 2020,
the World Health Organization declared COVID-19 a pandemic. People with underlying …
the World Health Organization declared COVID-19 a pandemic. People with underlying …
Initiation of antiretroviral therapy in early asymptomatic HIV infection.
…, B Grund, S Sharma, A Avihingsanon… - The New England …, 2015 - europepmc.org
Background Data from randomized trials are lacking on the benefits and risks of initiating
antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) …
antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) …
Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand
…, S Kiertiburanakul, A Avihingsanon… - AIDS research and …, 2015 - Springer
New evidence has emerged regarding when to commence antiretroviral therapy (ART),
optimal treatment regimens, management of HIV co-infection with opportunistic infections, and …
optimal treatment regimens, management of HIV co-infection with opportunistic infections, and …
Treatment strategy for rifampin-susceptible tuberculosis
…, C Sekaggya-Wiltshire, A Avihingsanon… - … England Journal of …, 2023 - Mass Medical Soc
Background Tuberculosis is usually treated with a 6-month rifampin-based regimen.
Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear. …
Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear. …
Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a …
…, FA Post, M Bloch, A Avihingsanon… - JAIDS Journal of …, 2016 - journals.lww.com
Background: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal
and bone safety compared with TDF-containing regimens. We report the 48 week safety and …
and bone safety compared with TDF-containing regimens. We report the 48 week safety and …
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
…, V Gioukari, O Anagnostou, A Avihingsanon… - The Lancet …, 2019 - thelancet.com
Background Since the 1918 influenza pandemic, non-randomised studies and small clinical
trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous …
trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous …
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
…, I Brates, C Scello, A Son, A Avihingsanon… - The Lancet …, 2022 - thelancet.com
Background Despite widespread availability of direct-acting antivirals including generic
formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) …
formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) …
[PDF][PDF] A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand
Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is
associated with considerable liver disease morbidity and mortality. Emerging HIV epidemics in …
associated with considerable liver disease morbidity and mortality. Emerging HIV epidemics in …
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study
…, M Johnson, E Voronin, D Hagins, A Avihingsanon… - The lancet HIV, 2016 - thelancet.com
Background Women are under-represented in HIV antiretroviral therapy (ART) studies.
Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not contain sex…
Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not contain sex…
